hotspot -WSS

hotspot

author：knowledge 2025-10-02 05:30:55 - browse：6437

Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.

The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.

RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Is mRNA technology the right fit for flu shots? Experts aren’t so sure

WSS

3 hurdles to bringing medical devices to the U.S. market

With clinical trial data readouts, here's how to spot spin

Pediatric cancer treatments threatened by a new FDA policy

The strategy behind pharma's lawsuits over drug pricing reform

FDA investigates CAR

Ask STAT: What do you want to know about ChatGPT in medicine?

leisure time

hotspot

focus

Supreme Court strikes down use of affirmative action

The battle over the Brookhaven Landfill on Long Island

In Memoriam: Notable people who died in 2023

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Fetal surgery at risk from Dobbs and new abortion restrictions

Anesthesiologist group: stop taking Ozempic before surgery

What don’t we know about an Alzheimer’s drug side effect?

Apple is now the first public company to be valued at $3 trillion

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

3 hurdles to bringing medical devices to the U.S. market

CDC director unscathed in first congressional testimony

Takeda, Janssen join wearable maker to measure scratching

STAT's guide to the next generation of CAR

In areas with more Black doctors, Black people live longer

Fetal surgery at risk from Dobbs and new abortion restrictions

explore

entertainment

entertainment

knowledge